Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab–bendamustine in follicular lymphoma: a single-center case series study
Abstract Rituximab and obinutuzumab, anti-CD20 monoclonal antibodies, are widely employed for treatment of follicular lymphoma (FL) by targeting both neoplastic and normal CD20-expressing B lymphocytes, consequently inducing immunosuppression. In this condition, viral reactivations are common and re...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Springer
2025-11-01
|
| سلاسل: | Journal of Cancer Research and Clinical Oncology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1007/s00432-025-06351-2 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|